 The FDA has approved Oyster Point Pharma Inc NASDAQ: OYST Tyrvaya varenicline solution Nasal Spray 0.03 mg for signs and symptoms of dry eye disease. Tyrvaya Nasal Spray is the first and only nasal spray approved for dry eye disease. 